Mercury Securities
  • Try MST28 trading from Mercury Securities with rates as low as 0.05%.
  • Earn MS Coin when you trade with MST28. Check out MST28.
  • Try MST28 trading from Mercury Securities with rates as low as 0.05%.
  • Get FREE real time quotes on our website & App. Check out MST28.
Open Trading Account
add free Download App
premium Premium Account

Last Price Change Volume
KLSE Market Watch
Open: Day Range: Prev Close:


Bintai Kinden Corporation Berhad ("BKCB" or "Company")

BINTAI KINDEN CORPORATION BERHAD

Type Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID IQL-18082020-00002
Subject Bintai Kinden Corporation Berhad ("BKCB" or "Company")
Description
MEMORANDUM OF UNDERSTANDING  BETWEEN BKCB AND NUGENEREX IMMUNO-ONCOLOGY 
ON NEW BUSINESS OPPORTUNITY (COVID-19 VACCINE)
Query Letter Contents

We refer to your Company’s announcement dated 17 August 2020 in respect of the aforesaid matter.


In this connection, kindly furnish Bursa Securities with the following additional information for public release:-

 

1) To provide the specific roles and responsibilities of BKCB and Generex respectively under the collaboration.


2) To state the estimated total capital and investment outlay, and the source of funds for the collaboration.


3) What is the stage of development and clinical trials of the Covid-19 Vaccine developed by Generex and whether necessary approvals have been obtained from the relevant government/medical  authorities. If yes, to provide the name thereof.

 

4) To elaborate on the strategy that the parties had laid down in the preparation of the Project.

 

5) To provide further details on the"li-Key immune system activation technology".

 

6) Please explain whether BKCB has the required and relevant expertise in the medical field to undertake the relevant production and/or distribution of the Covid-19 Vaccine. If yes, to provide the background information such as educational, nationality and past working experiences of such person. In addition, to also provide the following additional information (where relevant):-

 

(i) details of the production facilities, including the location, production capacity and whether such facilities are subject to any government authorities' approval/consent; and

 

(ii) the distribution channel for the sale of the Covid-19 Vaccine.

 

7) Risk factors in relation to the collaboration that BKCB may be exposed to and the mitigating factors.

 

8) The target market under the collaboration and whether any contract has been secured. 

 

9) Whether necessary approval have been obtained for distribution and marketing of the Covid-19 Vaccine.

 

Please furnish Bursa Securities with your reply within one (1) market day from the date hereof.

 

Yours faithfully,

 

Listing

Regulation
 

Cc : Market Surveillance Dept. , Securities Commission (via fax)

Reference is made to the Company's announcement released on 18 August 2020 on the Memorandum of Understanding ("MOU") between BKCB and Nugenerex Immuno-Oncology on the new business opportunity on Covid-19 vaccine.

 

Unless otherwise stated, abbreviations adn definitions used throughout this announcement shall be the same as those previously defined in the previous announcement dated 18 August 2020 in relation to the MOU.

 

Please refer to the attachment for the additiional information requested.

 

This announcement is dated 19 August 2020.



Please refer attachment below.



Announcement Info

Company Name BINTAI KINDEN CORPORATION BERHAD
Stock Name BINTAI
Date Announced 19 Aug 2020
Category General Announcement for PLC
Reference Number GA1-19082020-00046




Close